independence in this high-risk subset of patients are not well defined. We demonstrate that urgent carotid interventions can be safely performed in select patients with minor to moderate strokes (NIHSS score <10) after 48 hours, resulting in functional independence as assessed by use of the mRS score on discharge. Carotid interventions done within 48 hours are associated with significantly increased risks. Improved safety of delaying urgent carotid interventions for 48 hours within stroke presentation has previously been demonstrated in a large Swedish Vascular Registry study. 4 However, to our knowledge, this is the first time that neurologic functional outcomes have been correlated with presenting stroke severity and time to intervention for acute CEA and CAS. By demonstrating a clear correlation between admission NIHSS score and interval time to procedure with independent functional outcomes, we aimed to clarify clinical decision-making for patients presenting with acutely symptomatic carotid lesions.
Treatment Strategies and Outcomes of Infections After Carotid Interventions
Vincent Federico, Javairiah Fatima, Salvatore Scali, Robert Feezor, Scott Berceli, Kristina Giles. Thomas Huber University of Florida, Gainesville, Fla Background: Infections after carotid endarterectomy are a devastating but rare complication, with paucity of literature providing guidelines for management of this complex issue. In this study, we report the experience of a single institution's management of carotid infections occurring after carotid interventions.
Methods: A retrospective chart review was performed to document presentation, treatment, and outcomes of patients who underwent surgical intervention for carotid infections from 2002 to 2017. Primary end points were mortality and stroke. Secondary end points were cranial nerve injuries, reinfections, and reinterventions.
Results: Twenty-nine patients with mean age of 69 6 2 years (76% male) were treated for carotid infections. Index operation was performed elsewhere in 27 (93%) patients, and 7 (24%) of these patients had prior secondary reinterventions (4 had carotid stenting and 3 had surgical revisions). The most common symptom on presentation was abscess or purulent drainage in 19 (66%) patients; 7 (24%) patients presented with active bleeding, and 10 (34%) patients had carotid pseudoaneurysms. Computed tomography was the diagnostic imaging of choice in 27 of 29 (93%) patients. Incision and drainage were performed in seven patients (five of these were done elsewhere before transfer). Wound and blood cultures were positive in 16 and 2 patients, respectively; the most common organisms identified were staphylococcus and streptococcus (83%). A combination of prosthetic (n ¼ 15) and bovine (n ¼ 5) patches was used at index operation. Median time to presentation was 7 months (range, 0.3-194 months) . Femoral vein graft interposition was used for carotid replacement in 24 patients (83%), femoral vein patch angioplasty in 1 (3%), and saphenous vein patch angioplasty in 4 (14%). Early complications included stroke in one patient (3%) and death in one patient on postoperative day 11 from multiorgan system failure (3%). Three patients had tracheostomy (one for prolonged ventilator dependence, one had bilaterally paretic vocal cords, and one had a history of radiation therapy for laryngeal cancer). Cranial nerve injury occurred in eight patients (28%); all resolved at last follow-up. Mean length of hospital stay was 10 6 1 days. Background: The aim of this study was to report the 1-year outcomes of the transcarotid artery stenting (TCAR) with cerebral blood flow reversal (ROADSTER) multicenter trial and to evaluate the durability of TCAR. This trial introduced a novel transcarotid neuroprotection system (ENROUTE Transcarotid NPS; Silk Road Medical Inc, Sunnyvale, Calif). Overall 30-day stroke rate was 1.4%, which was the lowest reported in any clinical trial for carotid artery stenting.
Methods: This study is a prospective, single-arm clinical trial. Enrollment occurred in 14 centers. Primary end points were incidence rates of ipsilateral stroke and death at 1 year after TCAR. Occurrence of stroke was ascertained by an independent clinical event committee.
Results: Overall, 219 patients were enrolled (pivotal phase, 141; extended access, 78 patients). Of those, 164 patients were included in the 1-year follow-up (16 had postoperative events, 3 died, 10 declined to participate, and 26 were lost to follow-up). Mean age was 73.9 years (range, 42.1-91.3 years). Patients aged 75 years and older were 43.3% of the cohort; 34.8% of patients were female, 92.7% were white, and 5.5% were African American. Most patients were asymptomatic (79.9%). Patients with anatomic risk factors were distributed as follows: contralateral carotid artery occlusion, 11.0%; tandem stenosis of >70%, 1.8%; high cervical carotid artery stenosis, 25.0%; restenosis after CEA, 25.6%; and bilateral stenosis requiring treatment, 4.3%. Hostile neck was the indication for TCAR in 14.6% of cases. Physiologic high-risk factors including two-vessel coronary artery disease were reported in 14.0% of the participants, and severe left ventricular dysfunction (left ventricular ejection fraction <30%) was reported in three (1.8%) patients. Overall, anatomic and physiologic highrisk factors were reported in 43.3% and 29.9% of patients, respectively. Both subsets of factors were present in 26.8% of the entire cohort. At 1-year follow-up, ipsilateral stroke incidence rate was 0.6%, and overall mortality rate was 3.7%. The 1-year risk of stroke found in this study is the lowest to date to be reported in any Food and Drug Administration-approved carotid stent (Fig) .
Conclusions: Transcarotid artery revascularization with dynamic flow reversal had previously shown favorable 30-day perioperative outcomes. This excellent performance seems to extend to 1 year after TCAR as illustrated in this analysis. The promising results from the ROADSTER trial might stem from the novel cerebral protection provided through the ENROUTE Transcarotid NPS in comparison to distal protection devices. The transcervical approach circumvents aortic arch manipulation that takes place through the transfemoral approach. TCAR offers a potentially safe alternative option for patients who are deemed to be at high risk for CEA.
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Contemporary Clinical and Financial Analysis of Open Versus Percutaneous Mechanical Thrombectomy for Occluded Hemodialysis Access
Results [n ¼ 25] ) showed that RT therapy had lower estimated blood loss (P < .001) and shorter operative time (RT, 48 minutes; PMT, 52 minutes; P < .03). The highest successful thrombectomy rate was RT (97.7% RT vs 94.7%; P < .07). Financially, all economic end points, specifically direct supply cost (OST, $3334; RT, $3241; PMT, $3529; RT + PMT, Fig. Long-term ipsilateral stroke rates of FDA-approved carotid stents.
